NewAmsterdam Pharma Co N.V.
NAMSWDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How NAMSW's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib 10mg | Phase 2 | Antioxidant Absorption | - | - |
Frequently asked questions
What is in NewAmsterdam Pharma Co N.V.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in NewAmsterdam Pharma Co N.V.'s (NAMSW) pipeline across Phase 3, Phase 2. Its lead program is Obicetrapib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NewAmsterdam Pharma Co N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NewAmsterdam Pharma Co N.V. (NAMSW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NAMSW biotech catalysts?→
Add NAMSW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NewAmsterdam Pharma Co N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.